259 related articles for article (PubMed ID: 38075413)
21. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
Jensen IS; Wu E; Fan W; Lodise TP; Nicolau DP; Dufour S; Cyr PL; Sulham KA
J Manag Care Spec Pharm; 2016 Jun; 22(6):752-64. PubMed ID: 27231802
[TBL] [Abstract][Full Text] [Related]
22. Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study.
Anastasio PJ; Wolthoff P; Galli A; Fan W
Infect Dis Ther; 2017 Mar; 6(1):115-128. PubMed ID: 28078655
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
Jame W; Basgut B; Abdi A
PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
[TBL] [Abstract][Full Text] [Related]
24. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
[TBL] [Abstract][Full Text] [Related]
25. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
[TBL] [Abstract][Full Text] [Related]
26. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
27. Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.
Keyloun KR; Lofgren E; Hebert S
J Med Econ; 2019 Jul; 22(7):652-661. PubMed ID: 30838908
[No Abstract] [Full Text] [Related]
28. Oritavancin: A Novel Lipoglycopeptide.
Mattox J; Belliveau P; Durand C
Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
[TBL] [Abstract][Full Text] [Related]
29. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
Dimopoulou D; Mantadakis E; Koutserimpas C; Samonis G
Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887193
[TBL] [Abstract][Full Text] [Related]
30. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
31. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
Brade KD; Rybak JM; Rybak MJ
Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
[TBL] [Abstract][Full Text] [Related]
32. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
[TBL] [Abstract][Full Text] [Related]
33. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
34. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.
Morrisette T; Miller MA; Montague BT; Barber GR; McQueen RB; Krsak M
J Antimicrob Chemother; 2019 Aug; 74(8):2405-2416. PubMed ID: 31322694
[TBL] [Abstract][Full Text] [Related]
35. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.
Jean SS; Liu IM; Hsieh PC; Kuo DH; Liu YL; Hsueh PR
Int J Antimicrob Agents; 2023 May; 61(5):106763. PubMed ID: 36804370
[TBL] [Abstract][Full Text] [Related]
36. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
[TBL] [Abstract][Full Text] [Related]
37. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
[TBL] [Abstract][Full Text] [Related]
38. Long-Acting Lipoglycopeptides Can Interfere With Vancomycin Therapeutic Drug Monitoring.
Smelter DF; Trisler MJ; McCreary EK; Baker M; Copeland K; Dilworth TJ; Rose WE
J Clin Pharmacol; 2022 Apr; 62(4):472-478. PubMed ID: 34564865
[TBL] [Abstract][Full Text] [Related]
39. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
[TBL] [Abstract][Full Text] [Related]
40. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
